Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-01-30
DOI
10.3389/fphar.2019.01672
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients
- (2019) Tycho Heimbach et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
- (2019) Jeffry Adiwidjaja et al. CLINICAL PHARMACOKINETICS
- Ontogeny of Phase I Metabolism of Drugs
- (2019) Karel Allegaert et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling
- (2019) Youwei Bi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters
- (2019) Kit Wun Kathy Cheung et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building
- (2019) Khaled Abduljalil et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic studies in children: recommendations for practice and research
- (2018) Charlotte I S Barker et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
- (2018) Eva Germovsek et al. CLINICAL PHARMACOKINETICS
- State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
- (2018) Venkata Yellepeddi et al. CLINICAL PHARMACOKINETICS
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
- (2018) Meinolf Suttorp et al. LEUKEMIA
- Physiologically based pharmacokinetic modelling to guide drug delivery in older people
- (2018) Manoranjenni Chetty et al. ADVANCED DRUG DELIVERY REVIEWS
- Development of a PBPK Model for Mefloquine and its Application alongside a Clinical Effectiveness Model to Select an Optimal Dose for Prevention of Malaria in Young Caucasian Children
- (2018) Trevor N. Johnson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities
- (2018) Sara N. Salerno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology
- (2018) Manuela Grimstein et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pharmacology and pharmacokinetics of imatinib in pediatric patients
- (2017) Meinolf Suttorp et al. Expert Review of Clinical Pharmacology
- Role of pharmacogenetics in personalised imatinib dosing
- (2017) Daniel T. Barratt et al. Translational Cancer Research
- Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer
- (2016) Christopher Walsh et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
- (2016) Eva Germovsek et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
- (2016) Sander Bins et al. CLINICAL PHARMACOKINETICS
- Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics
- (2016) B Prasad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure
- (2016) Andrew Rowland et al. Expert Opinion on Drug Metabolism & Toxicology
- Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
- (2016) Claudia Neul et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site
- (2015) Helen Musther et al. AAPS Journal
- Paediatric pharmacokinetics: key considerations
- (2015) Hannah Katharine Batchelor et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension
- (2015) Didier Renard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel
- (2015) Hoai-Thu Thai et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling
- (2015) Vijay V. Upreti et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Managing children with chronic myeloid leukaemia (CML)
- (2014) Josu de la Fuente et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data
- (2014) Farzaneh Salem et al. CLINICAL PHARMACOKINETICS
- Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
- (2014) K R Schultz et al. LEUKEMIA
- Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children
- (2014) Christian Diestelhorst et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia
- (2014) Kazuaki Taguchi et al. PEDIATRICS INTERNATIONAL
- A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam
- (2013) A. R. Maharaj et al. AAPS Journal
- Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite
- (2013) A M Filppula et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-Drug Interactions
- (2013) Farzaneh Salem et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Do Children Have the Same Vulnerability to Metabolic Drug-Drug Interactions as Adults? A Critical Analysis of the Literature
- (2013) Farzaneh Salem et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Pharmacokinetic Standard for Babies and Adults
- (2013) Nick Holford et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
- (2013) Bernadette Anna Sophia Jaeger et al. MEDICAL SCIENCE MONITOR
- Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes
- (2013) Verena Gotta et al. THERAPEUTIC DRUG MONITORING
- Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
- (2012) Amina Haouala et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
- (2012) Peggy Gandia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
- (2012) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
- (2011) AM Filppula et al. BRITISH JOURNAL OF PHARMACOLOGY
- Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children
- (2011) Gisela Kersting et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model
- (2011) A. S. Darwich et al. CURRENT DRUG METABOLISM
- Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
- (2011) Frédéric Millot et al. JOURNAL OF CLINICAL ONCOLOGY
- Tips and traps analyzing pediatric PK data
- (2011) Brian J. Anderson et al. PEDIATRIC ANESTHESIA
- PharmGKB summary
- (2011) Caroline F. Thorn et al. Pharmacogenetics and Genomics
- Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
- (2011) Helen E. Cubitt et al. XENOBIOTICA
- Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450
- (2010) Y. Chen et al. DRUG METABOLISM AND DISPOSITION
- Imatinib mesylate in children and adolescents with cancer
- (2010) Ronald D. Barr PEDIATRIC BLOOD & CANCER
- Impact of OATP transporters on pharmacokinetics
- (2009) A Kalliokoski et al. BRITISH JOURNAL OF PHARMACOLOGY
- Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
- (2009) Birgit Geoerger et al. EUROPEAN JOURNAL OF CANCER
- A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
- (2009) Sylvain Baruchel et al. EUROPEAN JOURNAL OF CANCER
- Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam
- (2009) Karen Rowland Yeo et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
- (2008) Divya Menon-Andersen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias
- (2008) Elena Marangon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
- (2008) A. Petain et al. CLINICAL CANCER RESEARCH
- Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
- (2008) Jiansong Yang et al. CURRENT DRUG METABOLISM
- The problems in scaling adult drug doses to children
- (2007) T N Johnson ARCHIVES OF DISEASE IN CHILDHOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started